Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

BACKGROUND: Bevacizumab (Bev) has gained acceptance as an active agent in the treatment of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who are re-treated with Bev after achieving a complete response to a Bev-containing regimen (BCR). Our primary objective was to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: McCann, Georgia A., Smith, Blair, Backes, Floor J., Rath, Kellie, Chacko, Simi, Salani, Ritu, Eisenhauer, Eric, Fowler, Jeffrey, Cohn, David, Copeland, Larry, O’Malley, David
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3886294/
https://ncbi.nlm.nih.gov/pubmed/22885866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados